Working… Menu

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer (PANDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02127151
Recruitment Status : Withdrawn (Withdrawal of Industry support for the study)
First Posted : April 30, 2014
Last Update Posted : December 15, 2015
Medivation, Inc.
Information provided by (Responsible Party):
University College, London

Brief Summary:

A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis

PTEN= Phosphatase and tensin homolog MSI= Microsatellite instability MRE11= Double-strand break repair protein MRE11A

This trial will investigate whether the drug BMN 673 has therapeutic benefit in the treatment of advanced endometrial cancer. Nearly 8,000 patients are diagnosed with endometrial cancer in the UK every year. A significant proportion are either diagnosed with advanced disease which may be inoperable and/or metastatic (i.e spread to other organs outside the endometrium), or curable disease which relapses following first line treatment. There is no established standard of care for these patients as both chemo and hormone therapy has limited effectiveness and survival benefit. Survival rates have not improved in the past 20 years. Furthermore there are no so called 'targeted' drugs licensed for its treatment i.e. drugs that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. This leaves an unmet need for effective systemic treatments for advanced, inoperable and metastatic endometrial cancer.

BMN 673 has been shown to be potentially effective in treating cancers known to behave similarly to endometrial disease, both in the laboratory and in Phase I studies involving patients with advanced cancers. Similarly the drug appears to be relatively tolerable. A Phase II trial such as the one proposed by this application could demonstrate activity that might lead to a new effective treatment for patients with inoperable, advanced, recurrent or metastatic endometrial cancer, while the proposed substudy also presents the possibility of discovering a subset of patients more likely to derive benefit from BMN 673.

This trial is for adult women (18 and above) with advanced, inoperable or metastatic endometrial cancer. Patients will be recruited from approximately 15 National Health Service (NHS) Trusts based in the United Kingdom (UK). The study is expected to last approximately 18-24 months in terms of recruitment time, and a maximum of 100 eligible women will be registered. All patients will receive BMN 673 until their disease worsens or their doctor decides they should stop treatment.

Condition or disease Intervention/treatment Phase
Endometrial Cancer Drug: BMN 673 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis
Estimated Primary Completion Date : October 2018

Arm Intervention/treatment
Experimental: BMN 673
BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
Drug: BMN 673
Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.

Primary Outcome Measures :
  1. Progression free survival (PFS) rate [ Time Frame: 6 months ]
    Measured from date of first BMN 673 dose to first progression (defined using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1) or death, whichever is the sooner.

Secondary Outcome Measures :
  1. Best Response [ Time Frame: Up to 30 months ]
    Measured from the date of first BMN 673 dose.

  2. Overall survival (OS) [ Time Frame: Up to 30 months ]
  3. Response at each radiological assessment [ Time Frame: Up to 30 months ]
  4. Duration of Response (DoR) [ Time Frame: Up to 30 months ]
  5. Median PFS [ Time Frame: Up to 30 months ]
  6. Safety and toxicity [ Time Frame: Up to 30 months ]
    Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade 3-4 toxicity; dose reductions, omissions, delays; exposure; compliance.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically confirmed endometrial cancer. All histological subtypes except for carcinosarcoma are eligible
  • Evidence of inoperable, advanced, recurrent or metastatic disease by imaging and/or histological criteria
  • ≤ 1 previous line of systemic cancer therapy for inoperable, advanced, recurrent or metastatic endometrial cancer. Chemotherapy in the adjuvant setting is not considered a prior line of therapy unless recurrence occurred during adjuvant treatment or ≤ 6 months after the last treatment; first line treatment of advanced disease must include at least one cytotoxic agent to be considered as a line of therapy; prior hormonal treatment is not considered a line of therapy in any setting
  • Written informed consent obtained prior to any screening procedures
  • Patients must give consent for provision of archival histological tissue for the purposes of translational research. If archival tissue is not available or is of insufficient quantity and/or quality, the patient will have the option to consent to undergo biopsy where feasible. If biopsy is not feasible or the patient does not give consent for biopsy when archival tissue is not available, the patient will not be eligible for the trial. The quality and quantity of archival tissue will be assessed by a suitably qualified individual, usually a histopathologist, at site to ensure adequate tissue sample available for testing PTEN, MSI and MRE11
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
  • Life expectancy ≥ 12 weeks
  • Patient has at least one site of measurable disease on radiological imaging (i.e. target lesion) as per RECIST v1.1
  • Evidence of non-childbearing status and must not be lactating OR must have postmenopausal status
  • Adequate bone marrow and organ function

Exclusion Criteria:

  • Prior treatment with a poly adenosine diphosphate ribose polymerase (PARP) inhibitor
  • Progressive disease ≤ 3 months after platinum-based chemotherapy
  • Active uncontrolled infection including known Hepatitis B, Hepatitis C or HIV
  • Obstruction of the gastrointestinal tract or other reason preventing effective oral administration of medication
  • Serious concomitant non-malignant disease, uncontrolled organ dysfunction or medical disorder considered by the Investigator to make the subject unsuitable for trial participation including any psychiatric disorder that prevents informed consent
  • Significant active cardiovascular disease
  • Symptomatic brain metastases
  • Immunosuppressant therapy or considered to be otherwise immunocompromised
  • Myelodysplastic syndrome/acute myeloid leukaemia
  • Major surgery ≤ 28 days prior to registration, or ongoing clinically significant post-surgical complications
  • Chemotherapy, radiotherapy (a single fraction of palliative radiotherapy is allowed provided that the site being treated is not subsequently used as a target lesion as per RECIST v1.1 for the purpose of assessing tumour response on trial), immunotherapy or other investigational therapy for cancer ≤ 21 days prior to registration (42 days for nitrosoureas, mitomycin-C)
  • Unresolved clinically significant toxicities from prior systemic therapy
  • Known hypersensitivity to any of the agents or excipients to be administered
  • Unwillingness or inability to comply with the trial protocol
  • Patients with a history of other malignancy ≤ 3 years prior to registration with the exceptions of a) cone-biopsied in situ carcinoma of the cervix uteri; b) basal or squamous cell carcinoma of the skin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02127151

Layout table for location information
United Kingdom
Royal Sussex County Hospital
Brighton, East Sussex, United Kingdom, BN2 5BE
The Beatson West of Scotland Cancer Centre
Glasgow, Greater Glasgow, United Kingdom, G12 0YN
St Bartholomew's Hospital
London, Greater London, United Kingdom, EC1A 7BE
University College Hospital
London, Greater London, United Kingdom, NW1 2BU
The Christie Hospital
Manchester, Greater Manchester, United Kingdom, M20 4BX
Western General Hospital
Edinburgh, Lothian, United Kingdom, EH4 2XU
The Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Velindre Cancer Centre
Cardiff, South Glamorgan, United Kingdom, CF14 2TL
St James's University Hospital
Leeds, South Yorkshire, United Kingdom, LS9 7TF
Royal Marsden Hospital (Sutton)
Sutton, Surrey, United Kingdom, SM2 5PT
The Clatterbridge Cancer Centre
Bebington, Wirral, United Kingdom, CH63 4JY
Bristol Haematology and Oncology Centre
Bristol, United Kingdom, BS2 8ED
East Kent Hospitals University NHS Foundation Trust
Kent, United Kingdom
The Royal Marsden Hospital (London and Surrey)
London and Surrey, United Kingdom
Guy's Hospital
London, United Kingdom, SE1 9RT
Northern Centre for Cancer Care
Newcastle, United Kingdom, NE7 7DN
Sponsors and Collaborators
University College, London
Medivation, Inc.
Layout table for investigator information
Principal Investigator: Rebecca Kristeleit University College, London

Additional Information:
Layout table for additonal information
Responsible Party: University College, London Identifier: NCT02127151     History of Changes
Other Study ID Numbers: UCL/13/0045
2013-003469-32 ( EudraCT Number )
First Posted: April 30, 2014    Key Record Dates
Last Update Posted: December 15, 2015
Last Verified: December 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents